BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Reference price $110.56 — last insider sale, 2026-04-22 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D52gen composite 70pct→79; net + operating loss
Notable findings
- No interest coverageInterest coverage -98.94 (cannot cover interest)
- Fund exitedNotable fund(s) exited this quarter: Bridgewater Associates, LP
- Net lossNet loss (net margin -39.6%)
- Material weakness– If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or
- Strong balance sheetStrong balance sheet — $9.0B cash & investments
- Trial readout soonUpcoming trial readout ~2026-06 — PHASE3 · Metastatic Breast Cancer
- Notable holderHeld by 5 notable fund(s): FMR LLC, CITADEL ADVISORS LLC, STATE STREET CORP +2 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: ARK Investment Management LLC
- Insider sellingInsider selling — 1 open-market sale(s) by 1 insider(s) (~$6M, last 6mo) Form 4 ↗
Key metrics
Gross margin
77.6%
Operating margin
-49.0%
Net margin
-39.6%
Return on equity
-5.9%
Return on assets
-5.2%
ROIC
-5.8%
Revenue growth (QoQ)
18.3%
Interest coverage
-98.9×
Current ratio
7.5×
Free cash flow
$330M
Tangible book value
$22.1B
Cash & investments
$9.0B
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Hanekamp Annemarie | Chief Commercial Officer | — |
| Jimenez Kylie | Chief People Officer | — |
| Poetting Sierk | Chief Operating Officer | — |
| Ryan James Timothy Patrick | See remarks. | — |
| Zapata Gomez Ramon | Chief Financial Officer | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-22 | Poetting Sierk | Sell | 50K | $110.56 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07361510 ↗ | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) Non-Small Cell Lung Cancer (NSCLC) | PHASE3 | Recruiting | 2031-10-14 |
| NCT07365995 ↗ | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Metastatic Castration-resistant Prostate Cancer | PHASE3 | Recruiting | 2031-02-01 |
| NCT05968326 ↗ | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC Adenocarcinoma, Pancreatic Ductal | PHASE2 | Recruiting | 2031-01-01 |
| NCT07079631 ↗ | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer Metastatic Colorectal Cancer | PHASE1/PHASE2 | Recruiting | 2030-12-01 |
| NCT07455734 ↗ | Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors Advanced Solid Tumor Cancer | PHASE1/PHASE2 | Recruiting | 2030-10-01 |
| NCT06953089 ↗ | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Solid Tumors | PHASE2 | Recruiting | 2030-06-30 |
| NCT07186842 ↗ | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 Advanced Solid Cancers | PHASE1/PHASE2 | Recruiting | 2030-05-01 |
| NCT05142189 ↗ | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer Non-Small Cell Lung Cancer | PHASE1 | Recruiting | 2030-02-01 |
| NCT07173751 ↗ | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer Breast Neoplasms | PHASE3 | Recruiting | 2029-12-01 |
| NCT07293351 ↗ | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Advanced Renal Cell Carcinoma (RCC) | PHASE1/PHASE2 | Recruiting | 2029-11-28 |
| NCT07291076 ↗ | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) Hepatocellular Carcinoma (HCC) | PHASE1/PHASE2 | Recruiting | 2029-10-15 |
| NCT06827236 ↗ | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer Locally Advanced Breast Cancer, Unresectable Breast Carcinoma | PHASE1/PHASE2 | Recruiting | 2029-08-01 |
| NCT04534205 ↗ | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer | PHASE2/PHASE3 | Recruiting | 2029-04-01 |
| NCT06712316 ↗ | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer Non-small Cell Lung Cancer | PHASE2/PHASE3 | Recruiting | 2029-02-01 |
| NCT07111520 ↗ | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer | PHASE1/PHASE2 | Recruiting | 2029-01-01 |
| NCT06712355 ↗ | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer Extensive-stage Small-cell Lung Cancer | PHASE3 | Recruiting | 2028-12-01 |
| NCT06841055 ↗ | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment Non-small Cell Lung Cancer | PHASE2 | Recruiting | 2028-10-01 |
| NCT06892548 ↗ | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer Advanced Lung Cancer | PHASE1/PHASE2 | Recruiting | 2028-09-01 |
| NCT06449222 ↗ | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy Locally Advanced Breast Cancer, Triple Negative Breast Cancer | PHASE2 | Active Not Recruiting | 2028-08-01 |
| NCT06750185 ↗ | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors Advanced Solid Tumor | PHASE1 | Recruiting | 2028-06-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-10 | 2025-12-31 | 0001776985-26-000017 ↗ |
| 20-F | 2025-03-10 | 2024-12-31 | 0001776985-25-000013 ↗ |
| 20-F | 2024-03-20 | 2023-12-31 | 0001776985-24-000027 ↗ |
| 20-F | 2023-03-27 | 2022-12-31 | 0001193125-23-079791 ↗ |
| 20-F | 2022-03-30 | 2021-12-31 | 0001776985-22-000019 ↗ |
| 20-F | 2021-03-30 | 2020-12-31 | 0001564590-21-016723 ↗ |
| 20-F | 2020-03-31 | 2019-12-31 | 0001564590-20-014536 ↗ |